

Additional File 3: Intensity score of EMT changes in tumor metastases following five days of OXi4503, Sunitinib and combination treatments. E-cadherin expression decreased in all treatment groups but only reached significance in the OXi4503 treatment (*P=0.005). ZEB1 expression significantly increased in the Sunitinib and Sunitinib/OXi4503 combination treatments (*P<0.025). Vimentin expression revealed a significant increase following OXi4503 treatment (*P=0.037).